share_log

维康药业:产品血塞通分散片中选全国中成药采购联盟集中带量采购

Zhejiang Wecome Pharmaceutical: The product Xuesaitong dispersible tablets has been selected for the national centralized procurement by the Chinese Patent Medicine Procurement Alliance.

Breakings ·  Feb 11 11:25

Zhejiang Wecome Pharmaceutical announced that the company's product Xuesaitong dispersible tablets has been selected for the national centralized procurement by the Chinese Patent Medicine Procurement Alliance (first batch expansion follow-up). The sales revenue of Xuesaitong dispersible tablets in 2024 is expected to be approximately 26 million yuan, with the revenue from the 40-tablet package being around 4.8 million yuan. During the procurement period, Medical Institutions will prioritize the use of selected medicines, which will help expand product sales scale and increase market share, positively impacting the company’s future operating performance. However, the signing of the procurement agreement for Xuesaitong dispersible tablets and subsequent matters and their impact are still uncertain.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 358

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.